Merck & Co., Inc. Open To More Biotech Deals After Idenix Pharmaceuticals, Inc.: Research Chief
(Reuters) - Merck & Co Inc's (MRK.N) research chief Roger Perlmutter said the No. 2 U.S. drugmaker would consider big acquisitions of biotech companies for their medicines, rather than to obtain their drug-development technologies.
Perlmutter, speaking on Thursday to analysts and investors at the annual Goldman Sachs healthcare conference being held near Los Angeles, said Merck continues to have an appetite for deals following its planned $3.85 billion purchase of Idenix Pharmaceuticals Inc (IDIX.O).
Help employers find you! Check out all the jobs and post your resume.